A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.
In an interview at AHA 2023, Deepak Bhatt, MD, MPH, discusses recent advancements in cardiovascular risk management, with a focus on the evolving recognition of inflammation, Lp(a), and obesity as modifiable risk factors.
UM Shore Regional Health Board of Directors Welcomes New Members talbotspy.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from talbotspy.org Daily Mail and Mail on Sunday newspapers.
Treatment with the aldosterone synthase inhibitor lorundrostat significantly decreased automated office systolic blood pressure in adults with uncontrolled hypertension in the phase 2 TARGET-HTN trial.